UK-based Domainex has purchased a Monolith NT.Automated instrument from NanoTemper Technologies.
The company has invested in the instrument to offer improved fragment-based drug discovery (FBDD) services to its partners and clients.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Domainex CSO Trevor Perrior said: “The combination of this technology with our proprietary Combinatorial Domain Hunting expertise will enable us to offer a unique protein production, characterisation, and fragment screening service at a speed and of a quality not matched by our competitors.
“The technology can significantly reduce the number of false positives and false negatives, meaning that we can find hits that may otherwise be overlooked.”
The device uses MicroScale Thermophoresis (MST) technology, which is used for quantifying molecular interactions and structural dynamics and presents binding affinity results in a short span of time.
NanoTemper Technologies CEO Dr Stefan Duhr said: ‘NanoTemper Technologies is extremely excited to announce Domainex as the first company in the UK to offer fragment screening services using our proprietary MST technology’.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“From our UK subsidiary in Cambridge we have an excellent relationship with Domainex and look forward to working with them in the future to deliver high-quality fragment screening results on novel targets.”
MST also offers several other advantages and can measure molecular interactions in solution at near native conditions, providing researchers with a choice of assay buffer systems.
The technology will enable the company to improve its FBDD processes and provide its partners with quality clinical candidate compounds.
